CEO Corner
- Home
- About Us
- CEO Corner
Understanding the Discontinuation of GLP-1 Medications
While GLP-1 medications like Ozempic and Wegovy have revolutionized the landscape of weight management and diabetes care, a growing trend of early discontinuation is raising questions among healthcare providers. In this edition of the CEO Corner, Waveny LifeCare Network President and CEO Russell Barksdale, Jr. explores the complex factors driving patients to stop these treatments—from high out-of-pocket costs and insurance barriers to the “perception of short-term use.”
March 18, 2025
At Waveny LifeCare Network, leadership is defined by more than operational excellence—it is rooted in guidance, education, and meaningful engagement with our community. Each month, Waveny CEO Russell R. Barksdale, Jr., PhD, MPA/MHA, FACHE, contributes his expertise to The New Canaan Sentinel, offering insightful commentary on healthcare, aging, and the values that shape compassionate, person-centered care.
In his recurring column, Dr. Barksdale addresses timely topics ranging from innovation in senior living and pharmaceutical research, to the essential role of human connection in caregiving, urgent regulatory matters and human behavioral issues. His perspectives draw on decades of experience leading mission-driven organizations and reflect a deep understanding of both the challenges and opportunities present in today’s healthcare environment.
Each editorial is grounded in a single, guiding commitment: improving the lives of the people we serve. We hope you find his reflections both informative and inspiring.